Spanish pharmaceutical Ferrer collaborates with Wellthy Therapeutics to enable a more personalized level of care with its products

March 31, 2020 | Case Study

Wellthy Therapeutics is an up-and-coming Indian startup that develops a prescription-only digital therapeutic (DTx) that is to be used to support treatment and the management of chronic diseases like diabetes. Based in India, the world's fastest-growing diabetes market, it is in an attractive position for companies looking to penetrate the Indian diabetes market. Wellthy has fully leveraged this position. It partnered with Roche to run a clinical study to test the test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's DTx. The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The company has also since been inducted into Bayer's highly competitive digital health accelerator, G4A (Grants for Apps). Wellthy continues to build on its momentum and has now inked a collaboration with Spanish pharmaceutical Ferrer.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978